Anti-Mullerian Hormone and conception timing as predictors of live births in cancer patients using fertility preservation: a systematic review.

ABSTRACT:

Objectives

Among women of childbearing potential aged 15-39, cancer incidence is 52.3 per 100,000 annually. Women newly diagnosed with cancer often have just 2-6 weeks to decide whether to pursue fertility preservation (FP) before commencing treatment. The recommended waiting period to conceive post-treatment ranges from 6 months to 5 years, depending on cancer type, treatment, and age. With >18 million young adult cancer survivors worldwide, identifying factors affecting fertility preservation and live birth outcomes is more critical than ever. This is the first systematic review to explore whether AMH levels before, during, or after chemotherapy predict pregnancy outcomes resulting from re-utilization of stored oocytes/embryos or spontaneous conception in cancer patients undergoi

SUBMITTER: Klonoff-Cohen H 

PROVIDER: S-EPMC12545013 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature